Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
1991-10-24
|
| pubmed:abstractText |
A child with acute myelogenous leukemia who relapsed three months after an allogeneic bone marrow transplant received intermediate-dose cytarabine followed by interleukin 2 (IL-2). Complete remission was achieved after the first cycle of IL-2. Five more combined cycles of cytarabine and IL-2 were given over the next year, during which remission has persisted. IL-2 therapy affected serum tumor necrosis factor (TNF), interferon gamma (IFN gamma) and soluble IL-2 receptor (sIL-2r) levels. In vitro cytotoxicity against leukemia cell lines and recipient leukemia cells was also increased.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0145-2126
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
15
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
759-63
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:1910127-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1910127-Bone Marrow,
pubmed-meshheading:1910127-Bone Marrow Transplantation,
pubmed-meshheading:1910127-Child, Preschool,
pubmed-meshheading:1910127-Combined Modality Therapy,
pubmed-meshheading:1910127-Cytarabine,
pubmed-meshheading:1910127-Female,
pubmed-meshheading:1910127-Humans,
pubmed-meshheading:1910127-Interferon-gamma,
pubmed-meshheading:1910127-Interleukin-2,
pubmed-meshheading:1910127-Leukemia, Myeloid, Acute,
pubmed-meshheading:1910127-Male,
pubmed-meshheading:1910127-Neutrophils
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
Therapy of advanced acute myeloblastic leukemia with cytarabine and interleukin 2.
|
| pubmed:affiliation |
Department of Pediatrics, University of Parma, Italy.
|
| pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|